TempraMed Signs Exclusive Kuwait Distribution Agreement With OGM

TempraMed entered an exclusive Kuwait distribution agreement with OGM For Import Medicine and Medical Supplies dated September 14, 2026. The initial 36-month term includes annual purchase commitments totaling approximately USD 500,000 in potential minimum purchases. Purchases are subject to regulatory clearance, continued agreement compliance and fulfillment of applicable purchase commitments. OGM will commercialize the medication temperature-protection portfolio in Kuwait, expanding the company's Gulf region distribution footprint. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempramed Technologies Ltd. published the original content used to generate this news brief via (Ref. ID: 202610150305NEWSFILECNPR____20261015_319020_1) on October 15, 2026, and is solely responsible for the information contained therein. (C)